Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

Jing Huang1,2,3†, Gang-Rui Hei1,2,3†, Ye Yang1,2,3, Chen-Chen Liu1,2,3, Jing-Mei Xiao1,2,3, Yu-Jun Long1,2,3, Xing-Jie Peng1,2,3, Yi Yang4, Jing-Ping Zhao1,2,3 and Ren-Rong Wu1,2,3,5*

1 Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China, 2 China National Clinical Research Center on Mental Disorders, Changsha, China, 3 China National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, China, 4 Mental Health Institute, Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, China, 5 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China

Weight gain and metabolic disturbances, potentially influenced by increased appetite, are common effects of olanzapine treatment in patients with schizophrenia. In this study, we explored the association between olanzapine-induced weight gain and metabolic effects with increased appetite. Drug-naïve, first-episode schizophrenia patients were treated with olanzapine for 12 weeks. Assessments included time to increased appetite, body weight, body mass index, biochemical indicators of blood glucose and lipids, proportion of patients who gained more than 7% or 10% of their baseline weight upon treatment conclusion, patients who developed dyslipidemia, and Positive and Negative Syndrome Scale scores. In total, 33 patients with schizophrenia receiving olanzapine were enrolled and 31 completed the study. During the 12-week olanzapine treatment, 77.4% (24/31) patients had increased appetite with 58.1% (18/31) patients having increased appetite within the first 4 weeks. The mean time for increased appetite was 20.3 days. More patients in the increased appetite group increased their initial body weight by more than 7% after 12 weeks when compared to patients with unchanged appetite (22/24 [91.7%] vs. 3/7 [42.9%], p = 0.004). Earlier increased appetite led to more weight gain during the following month. Overall, 50% of patients in the increased appetite group had dyslipidemia after 12 weeks. Our results demonstrated that olanzapine induced significantly appetite increase in first-episode patients with schizophrenia and appetite increase played a key role in olanzapine-induced weight gain and dyslipidemia.

Clinical Trial Registration: NCT03451734. Registered March 2, 2018 (retrospectively registered).

Keywords: antipsychotic drugs, appetite, olanzapine, schizophrenia, weight gain

Abbreviations: SGAs, Second-generation antipsychotics; RCT, Randomized clinical trial; CATE, The Comparison of Atypicals for First Episode; CATIE, The Clinical Antipsychotic Trials in Intervention Effectiveness; DSM-5, The Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition; ECG, Electrocardiogram; PANSS, The Positive and Negative Syndrome Scale; TESS, Treatment Emergent Symptom Scale; ELISA, Enzyme-linked immunosorbent assays; BMI, Body mass index; HDL-C, High-density lipoprotein; LDL-C, Low-density lipoprotein.
INTRODUCTION

Olanzapine is one of the most widely used second-generation antipsychotics (SGAs) for schizophrenia, bipolar disorder, and psychotic symptoms. Besides improving the main symptoms of psychosis, olanzapine shows great acceptability, decreases all-cause discontinuation, and prevents future relapse (Leucht et al., 2009). Many randomized clinical trials (RCTs) and meta-analyses have suggested that olanzapine is one of the most efficacious antipsychotic drugs in patients with schizophrenia (Leucht et al., 2013; Huhn et al., 2019).

The most common adverse effects of olanzapine is weight gain (Allison et al., 1999). Olanzapine elicits the most weight gain of the SGAs. The Comparison of Atypicals for First Episode (CAFE) trial demonstrated that 80% of patients treated with olanzapine gained more than 7% of their initial body weight at week 52 (McEvoy et al., 2007). The discontinuation rate of olanzapine due to weight gain or accompanying metabolic effects was 2–8 times higher than other antipsychotics in the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial (Lieberman et al., 2005). Besides being associated with decreased adherence with drug treatment, weight gain is also associated with substantial medical morbidity and mortality. Considering the high obesity rate in patients with schizophrenia (42%), the potential risk of olanzapine-induced weight gain should be evaluated carefully (Newcomer, 2006). Some randomized controlled trial (RCT) studies have found that patients with mental diseases die up to 30 years earlier than the general population (Das-Munshi et al., 2017). The leading cause of death in this population is heart disease. A major risk factor for heart disease and premature death in these patients is weight gain (Fekadu et al., 2015).

The mechanisms underlying antipsychotic-induced weight gain and adverse metabolic effects are not well understood (Correll et al., 2011). Olanzapine is associated with elevated appetite and food intake and decreased activity or impairment of metabolic regulation (Roerig et al., 2005; Henderson et al., 2015). Fountaine et al. reported that in healthy men, olanzapine increased body weight through increased food intake, without evidence of decreased activity or expenditure levels (Fountaine et al., 2010). This observation is in agreement with observations of male adolescent inpatients with schizophrenia (Gothelf et al., 2002). Patients had significantly increased body mass index due to increased caloric intake after 4-week olanzapine treatment (Gothelf et al., 2002). However, current evidence regarding the association of appetite with weight gain is inconclusive (Poyurovsky et al., 2007; Case et al., 2010). Case et al. reported that early appetite changes were not consistently correlated to overall weight change in four different trials (Case et al., 2010). Further, no study has reported the exact time of appetite increase, compared weight gain velocity relative to the timing of increased appetite, or assessed differences in weight gain and metabolic effects between patients with increased or unchanged appetite. Therefore, we evaluated the association between appetite increase and olanzapine-induced weight changes and accompanying metabolic effects in drug-naïve first-episode patients with schizophrenia.

MATERIALS AND METHODS

Participants

This study was conducted in the Mental Health Institute of the Second Xiangya Hospital, Central South University, China between December 2016 and April 2019. Participants were assessed for schizophrenia in accordance with criteria defined by the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) (A.P. Association, 2013). As antipsychotic-naïve/first episode patients appear to gain more weight after olanzapine treatment (Correll et al., 2011), we included first-episode schizophrenia patients aged 18–50 years were included in this study.

The exclusion criteria included (i) clinically abnormal findings of physical examinations, laboratory tests, or electrocardiogram (ECG) results; (ii) disorders such as intellectual disability, substance or alcohol use disorder, a diagnosis of other specific systemic diseases according to DSM-5 criteria; (iii) cardiovascular and metabolic diseases such as diabetes mellitus, dyslipidemia, and hypertension; (iv) a history of eating disorders; (v) strict diet within the month before screening or during the study; and (vi) pregnancy or lactating.

Intervention

Previous studies have suggested that the rate of olanzapine-induced weight gain was most rapid during the first 12 weeks of treatment (Correll et al., 2009). Therefore, participants were treated with olanzapine (15–20 mg/day at 8:00 p.m.) for 12 weeks. The initial dose of olanzapine was 5 mg/day and then adjusted to 15–20 mg/day in the first week.

Assessment

Baseline assessments included demographics, a thorough medical history, anthropometric measurements (weight and height), appetite, physical examination, and lab analysis. Appetite was assessed daily, 30 min before lunch, with four standardized questions: Hungry, Felt full, Thinking about food, and Overeating. Responses were graded on a scale from 0 to 10, where 0 = “not at all” and 10 = “extremely”. Appetite increase was defined as a >10% increases in baseline appetite scores. Appetite decrease was defined as a >10% decreases in baseline appetite scores. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the severity of schizophrenia symptoms. Adverse effects were evaluated by Treatment Emergent Symptom Scale (TESS). At each follow-up visit, all baseline evaluations (including physical examination, anthropometric measurements, appetite, and TESS) were repeated except PANSS. PANSS was re-evaluated at week 12.

Prior to treatment and in the fasting state, weight and height were measured after participants removed shoes with light indoor clothing. Appetite was assessed before lunch and was based on the judgement of the rating physician on examination day. Lab work including plasma glucose, liver, and renal function were evaluated using enzymatic procedures with the Boehringer Mannheim/Hitachi 714 automated chemistry analyzer. Insulin was measured with a solid-phase enzyme-linked immunosorbent assays (ELISA).
The primary outcomes were the percentage of patients who had increased appetite and period of time between olanzapine treatment and increased appetite. Secondary outcomes included changes in weight, body mass index (BMI), fasting glucose, fasting insulin and insulin resistance index, lipid profiles which included triglycerides, cholesterol, high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C), and PANSS score. BMI was calculated according to the criteria of the Working Group on Obesity in China: healthy weight (18.5 ≤ BMI < 25 kg/m²), overweight (25 ≤ BMI ≤ 28 kg/m²), and obese (BMI > 28 kg/m²). Dyslipidemia was defined as cholesterol ≥ 5.18 mmol/l, triglycerides ≥ 1.70 mmol/l, HDL-C < 1.04 mmol/l, or LDL-C ≥ 3.37 mmol/l based on the Chinese guidelines for dyslipidemia (Hu, 2017). An analysis of the proportion of patients who gained more than 7% of their baseline body weight after 12 weeks, which is the cutoff for clinically significant weight gain, was also included (Kanders et al., 1991).

Statistical Analysis
Statistical Package for Social Sciences, version 25.0 (SPSS v25.0) was employed for statistical analysis. Continuous variables and categorical variables are described using summary statistics (means and standard deviations) or frequencies and percentages, respectively. Student’s t-test and chi square analyses were used to analyze between-group differences in changes of body weight, BMI, fasting glucose and insulin, insulin resistance index, triglyceride, cholesterol, HDL-C, and LDL-C from baseline to each time point. We investigated the association between weight, BMI, insulin resistance index, LDL-C, and appetite using linear regression analysis. A P-value (p) < 0.05 was considered statistically significant.

RESULTS
In total, 33 schizophrenia inpatients (mean age, 23.5 years; range 18–36 years) were enrolled in the study. There was a higher proportion of female patients (63.6%, 21/33). All patients were in the normal BMI range (mean BMI, 21.3 ± 1.7 kg/m²). The mean duration of schizophrenia was 11.2 ± 3.7 (range 5–18) months. Two female patients dropped out of the study after 4 weeks because of increased appetite; the remaining 31 (93.9%) participants completed the study (Table 1).

Appetite Increase After Olanzapine Treatment
After 12-week olanzapine treatment, 77.4% (24/31) patients had increased appetite and 22.6% (7/31) patients had unchanged appetite. As shown in Figure 1, for the 24 patients who had increased appetite, the appetite increase began within the first 8 weeks of olanzapine treatment and lasted until the end of treatment. The mean time from olanzapine treatment initiation to appetite increase was 20.3 days (SD = 14.4), and 25.0% (6/24) and 70.8% (17/24) increased their appetite within 1 week and 4 weeks, respectively. Two patients increased their appetite on the 3rd day after olanzapine treatment. No significant difference was found in olanzapine-induced appetite between different genders using two-way analysis ANOVA.

Changes of Body Weight and BMI After Olanzapine Treatment
Significant increases in weight and BMI were observed after olanzapine treatment (Table 1). The mean weight gain was 7.9 kg during the 12-week period of olanzapine treatment, with patients gaining 2.4, 4.0, and 1.5 kg at the first, second, and third 4-week period, respectively. Female patients were more likely to gain weight (P < 0.001), with 9.19-kg mean weight gain during the study period compared with 5.90-kg weight gain in male patients. Of the total patients, 80.6% (25/31) and 61.3% (19/31) increased their initial body weight by more than 7% and 10%, respectively, during the 12-week olanzapine treatment (Supplementary Table 1). After 12 weeks, 51.6% (16/31) patients became overweight (BMI=25 kg/m²).

Changes of Metabolic Disturbances After Olanzapine Treatment
Significant increases in fasting glucose, fasting insulin, insulin resistance index, triglyceride, cholesterol, and LDL-C and decreases in HDL-C were observed at 12 weeks (Table 1). No patient included in the study had dyslipidemia at baseline. Based

**Figure 1** | Number of patients with increased appetite during 8-week olanzapine treatment periods.
on Chinese guidelines for dyslipidemia, 38.7% (12/31) of patients had dyslipidemia after 12 weeks of olanzapine treatment.

**Table 1 | Summary of weight and metabolic measures by study.**

| Variable and Week | Mean | SD | adjusted P Value |
|-------------------|------|----|------------------|
| **Weight (kg)** |      |    |                  |
| Week 0            | 56.69| 8.75| <0.001           |
| Week 4            | 59.05| 8.52|                 |
| Week 8            | 63.54| 8.09| <0.001           |
| Week 12           | 65.07| 8.11| <0.001           |
| **Body mass index (kg/m²)** |      |    |                  |
| Week 0            | 21.33| 1.72|                  |
| Week 4            | 22.24| 1.64| <0.001           |
| Week 8            | 23.92| 1.67| <0.001           |
| Week 12           | 24.51| 1.84| <0.001           |
| **Fasting glucose (mmol l⁻¹)** |      |    |                  |
| Week 0            | 4.39 | 0.36|                  |
| Week 4            | 4.48 | 0.40| 0.3460           |
| Week 8            | 4.57 | 0.34| 0.0038           |
| Week 12           | 4.60 | 0.33| 0.0020           |
| **Fasting insulin (mIU l⁻¹)** |      |    |                  |
| Week 0            | 7.81 | 1.74|                  |
| Week 4            | 8.38 | 2.08| 0.2841           |
| Week 8            | 10.57| 3.28| <0.001           |
| Week 12           | 13.94| 5.46| <0.001           |
| **Insulin resistance index** |      |    |                  |
| Week 0            | 1.53 | 0.39|                  |
| Week 4            | 1.67 | 0.44| 0.2219           |
| Week 8            | 2.15 | 0.71| <0.001           |
| Week 12           | 2.85 | 1.13| <0.001           |
| **Triglyceride (mmol l⁻¹)** |      |    |                  |
| Week 0            | 0.73 | 0.27|                  |
| Week 4            | 0.88 | 0.33| 0.0066           |
| Week 8            | 1.09 | 0.44| <0.001           |
| Week 12           | 1.27 | 0.55| <0.001           |
| **Cholesterol (mmol l⁻¹)** |      |    |                  |
| Week 0            | 3.73 | 0.48|                  |
| Week 4            | 3.61 | 0.48| 0.1811           |
| Week 8            | 3.89 | 0.55| 0.1511           |
| Week 12           | 4.17 | 0.77| 0.0022           |
| **HDL-C (mmol l⁻¹)** |      |    |                  |
| Week 0            | 1.22 | 0.13|                  |
| Week 4            | 1.22 | 0.15| 0.9939           |
| Week 8            | 1.17 | 0.16| 0.1412           |
| Week 12           | 1.09 | 0.25| 0.0134           |
| **LDL-C (mmol l⁻¹)** |      |    |                  |
| Week 0            | 2.10 | 0.35|                  |
| Week 4            | 2.12 | 0.39| 0.9972           |
| Week 8            | 2.43 | 0.51| 0.0039           |
| Week 12           | 2.59 | 0.61| <0.001           |

**Figure 2** showed the comparison of weight gain and metabolic-related outcomes between increased and unchanged appetite groups. Detailed analyses were presented in **Supplementary Table 2**. The weight gain between two groups was significant (P = 0.01) using two-way analysis ANOVA. The mean weight increased by 9.1 kg (SD = 4.1) in the appetite-increased group and 3.9 kg (SD = 2.0) in the unchanged appetite group with significant difference between the two groups during 12-week olanzapine treatment period. A greater percentage of patients (91.7%) in the increased appetite group gained more than 7% of their initial body weight after 12 weeks when compared to patients in the appetite unchanged group (42.9%; χ² = 8.27, df = 1, p = 0.004). Similarly, more patients in the increased appetite group (19/24, 79.2%) gained more than 10% of initial body weight after 12 weeks when compared to patients in the unchanged appetite group (0.0%; χ² = 14.32, df = 1, p < 0.001) (**Supplementary Tables 3–5**). After 12-week olanzapine treatment, 58.3% patients became overweight in the appetite increased group compared to 28.6% of patients in the unchanged appetite group. Appetite increase strongly mediated olanzapine-induced weight gain with mediating effect 66.2%.

**Appetite Increase and Olanzapine Induced Metabolic Disturbances**

There were significant differences in insulin (p = 0.017), insulin resistance index (p = 0.015), and LDL-C (p = 0.001) between the appetite increase and unchanged groups after 12 weeks (**Figure 2** and **Table 2**). Four patients in the increased appetite group had cholesterol ≥ 5.18 mmol l⁻¹, nine had triglycerides ≥ 1.70 mmol l⁻¹, six had HDL-C < 1.04 mmol l⁻¹, and three had LDL-C ≥ 3.37 mmol l⁻¹. In total, 13/24 patients in the increased appetite group had dyslipidemia after 12 weeks, while none of the patients in the unchanged appetite group developed dyslipidemia during the study period (**Table 3**).

**The Peak Weight Gain Reached 1 Month After the Month of Appetite Increase**

In the increased appetite group, we analyzed the mean weight gain for each patient at four time points: before the month of time to appetite increase (−1M), the month of time to appetite increase (0M), one month post-appetite increase (+1M), and two months post-appetite increase (+2M). Compared with −1M, there was an increase in weight gain at 0M, but this change was not significant (−1M vs. 0M, 1.4 ± 1.2 kg vs. 3.1 ± 1.4 kg). Weight gain entered peak growth at +1M, with a 4.3 ± 2.4 kg increase. Weight Growth decelerated at +2M (p < 0.001) by 1.6 ± 1.5 kg. The weight gain at +2M slowed down and stabilized, and no significant differences were observed when compared with −1M (**Figure 3** and **Supplementary Table 6**).

**Earlier Increased Appetite Predicts More Weight Gain in 1 Month After the Month of Appetite Increase**

We further compared the weight gain velocity of participants with increased appetite within 4 weeks (A) and participants with an increased appetite between 4 and 8 weeks (B). At 0M, the...
weight gain velocities between participants with increased appetite within 4 weeks and participants with an increased appetite between 4 and 8 weeks were not significantly different. However, participants with earlier increased appetite showed significantly increased weight gain velocity at +1M. These results demonstrated that earlier increased appetite might lead to more weight gain during the follow-up period (Figure 4). Similar changes in BMI were observed during the four time points (Figures 3 and 4).

**Appetite and Velocity of Metabolic Disturbance Changes**

Detailed descriptive data for changes in weight, BMI, fasting glucose, insulin, insulin resistance index, triglyceride, cholesterol, HDL-C, and LDL-C are summarized in Table 2. To investigate the association between increased appetite and glucose and lipid metabolism, we analyzed changes in these indicators at four time points in the increased appetite group. No significant velocity changes were observed for glucose, triglyceride, HDL-C, and LDL-C at any time point. Significant increases in velocities of insulin and insulin resistance index were only observed at +2M (Supplementary Figure 1 and Supplementary Table 6). Further comparisons suggested that participants with increased appetite within 4 weeks did not show significantly increased velocity of insulin and insulin resistance index at 0M and +1M compared to participants with increased appetite between 4 and 8 weeks (Supplementary Figure 2).

**The Prediction of Appetite on Olanzapine-Induced Weight Gain and Metabolic Disturbances**

We conducted linear regression analysis to evaluate the effect of appetite increase on weight gain, blood glucose, and lipid levels. After controlling for statistically significant variables such as sex, age, height, and duration, we included weight gain, BMI, fasting glucose, insulin, insulin resistance index, triglycerides, cholesterol, HDL-C, and LDL-C as dependent variables and appetite as the independent variable in the regression analysis. Appetite increase was associated with changes in weight ($\beta = 0.67$, $p = 0.0003$), BMI ($\beta = 0.63$, $p = 0.0004$), insulin ($\beta = 0.49$, $p = 0.019$), insulin resistance index ($\beta = 0.51$, $p = 0.0149$), and LDL-C ($\beta = 0.61$, $p = 0.0035$) (Supplementary Table 7).

Significant baseline-to-end point improvements of clinical symptoms (evaluated by PANSS, $p < 0.001$) were observed after...
olanzapine treatment. No significant difference in PANSS was observed between the increased appetite and unchanged appetite groups (p > 0.05).

**Adverse Effects**

Among all the 31 patients who completed the study, nine (29.0%) patients reported hypoactivity, eight (25.8%) patients reported somnolence, four (12.9%) patients had abnormal liver test, two (6.5%) patients reported akathisia, four (12.9%) patients had constipation, one (3.2%) patient had diarrhea, and two (6.5%) patients felt dizzy, and 80.6% (25/31) patients increased their body weight by more than 7% during the study period.

**DISCUSSION**

In this prospective study, the main findings showed that 77.4% patients increased their appetite after olanzapine treatment, and these patients who increased their appetite gained more weight than those patients with unchanged appetite (9.1 kg vs. 3.9 kg). Similarly, more patients in the increased appetite group increased their initial body weight by more than 7 or 10%, suggesting that increased appetite is associated with substantial weight gain in drug-naive first-episode schizophrenia patients treated with olanzapine. Moreover, linear regression analysis also supported that appetite increase was strongly related with olanzapine-induced weight gain. These findings were in accordance with previous reports (Gothelf et al., 2002; Cope et al., 2005). Murashita et al. (2005) observed increased appetite-stimulating ghrelin levels and body fat percentage in schizophrenia patients treated with olanzapine. Results from a randomized double-blind study suggested that olanzapine induced food craving and binge eating to a greater extent than clozapine (Murashita et al., 2005; Kluge et al., 2007). Similar results were also reported in mice treated with olanzapine (Cope et al., 2005). The action of olanzapine on multiple receptor sites, especially the D2 and 5H3 receptors, which modulate appetite, has also been applied in the treatment of anorexia nervosa and chemotherapy-induced nausea and vomiting (Kluge et al., 2007; Tan et al., 2009; Kafantaris et al., 2011).

### TABLE 2 | Descriptive statistics of outcome measures between increased and unchanged appetite groups at baseline, and weeks 4, 8, and 12.

| Measure                  | Baseline         | Week 4          | Week 8          | Week 12         | P-value | Sig  |
|--------------------------|------------------|-----------------|-----------------|-----------------|---------|------|
|                          | N    | Mean | s.d. | N    | Mean | s.d. | N    | Mean | s.d. | P-value | Sig  |
| Weight (kg)              |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 55.06 | 8.19 | 20   | 57.90 | 8.06 | 24   | 62.79 | 7.55 | <0.0001*** |      |
| Appetite unchanged       | 7    | 62.76 | 8.62 | 13   | 60.82 | 9.23 | 7    | 66.09 | 9.92 | <0.0001*** |      |
| Body mass index (kg/m2)  |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 21.09 | 1.74 | 20   | 22.23 | 1.68 | 24   | 24.07 | 1.67 | <0.0001*** |      |
| Appetite unchanged       | 7    | 22.24 | 1.42 | 13   | 22.26 | 1.66 | 7    | 23.39 | 1.70 | <0.0001*** |      |
| Fasting glucose (mmol/l-1)|      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 4.35  | 0.33 | 18   | 4.52  | 0.43 | 24   | 4.59  | 0.36 | <0.0001*** |      |
| Appetite unchanged       | 7    | 4.53  | 0.45 | 13   | 4.42  | 0.36 | 7    | 4.49  | 0.27 | <0.0001*** |      |
| Fasting insulin (mIU/l-1)|      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 7.58  | 1.62 | 18   | 8.14  | 1.73 | 24   | 10.53 | 3.18 | <0.0001*** |      |
| Appetite unchanged       | 7    | 8.64  | 2.03 | 13   | 8.72  | 2.52 | 7    | 10.71 | 3.88 | <0.0001*** |      |
| Insulin resistance index |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 1.47  | 0.34 | 18   | 1.63  | 0.34 | 24   | 2.16  | 0.70 | <0.0001*** |      |
| Appetite unchanged       | 7    | 1.76  | 0.51 | 13   | 1.72  | 0.56 | 7    | 2.13  | 0.80 | <0.0001*** |      |
| Triglyceride (mmol/l-1)  |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 0.72  | 0.27 | 18   | 0.94  | 0.36 | 24   | 1.14  | 0.48 | <0.0001*** |      |
| Appetite unchanged       | 7    | 0.76  | 0.30 | 13   | 0.78  | 0.28 | 7    | 0.92  | 0.28 |      | 0.0187* |
| Cholesterol (mmol/l-1)   |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 3.84  | 0.48 | 18   | 3.77  | 0.48 | 24   | 4.04  | 0.50 | <0.0001*** |      |
| Appetite unchanged       | 7    | 3.32  | 0.21 | 13   | 3.37  | 0.40 | 7    | 3.39  | 0.45 | <0.0001*** |      |
| HDL-C (mmol/l-1)         |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 1.24  | 0.13 | 18   | 1.23  | 0.15 | 24   | 1.17  | 0.19 | <0.0001*** |      |
| Appetite unchanged       | 7    | 1.18  | 0.13 | 13   | 1.21  | 0.15 | 7    | 1.14  | 0.06 | <0.0001*** |      |
| LDL-C (mmol/l-1)         |      |      |      |      |      |      |      |      |      |         |      |
| Appetite increased       | 26   | 2.15  | 0.35 | 18   | 2.07  | 0.38 | 24   | 2.56  | 0.46 | <0.0001*** |      |
| Appetite unchanged       | 7    | 1.92  | 0.29 | 13   | 2.19  | 0.42 | 7    | 1.98  | 0.48 | <0.0001*** |      |

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. * presents P < 0.05; **presents P < 0.01, *** presents P < 0.001.

### TABLE 3 | Dyslipidemia defined by each single outcome measurement in appetite increased and unchanged groups.

| Measure                  | Unchanged Appetite | Increased Appetite | Chi-Sq | P-value |
|--------------------------|--------------------|--------------------|--------|---------|
| Total sample             | 7                  | 24                 |        |         |
| Total cholesterol (≥5.18 mmol/l-1) | 0 | 0 | 4 | 16.7 | 1.34 | 0.247121 |
| Triglyceride (≥1.70 mmol/l-1) | 0 | 0 | 9 | 37.5 | 3.7 | 0.05445 |
| HDL-C (≥0.94 mmol/l-1) | 0 | 0 | 6 | 25 | 2.17 | 0.140726 |
| LDL-C (≥3.37 mmol/l-1) | 0 | 0 | 3 | 12.5 | 0.93 | 0.324992 |

Huang et al. Increased Appetite in Schizophrenia Patients

Frontiers in Pharmacology | www.frontiersin.org May 2020 | Volume 11 | Article 739
We also found that 70.8% patients increased their appetite within the first 4 weeks of initial olanzapine treatment with a mean of 20.3 days to increase. Some patients even increased their appetite as early as the third day after olanzapine treatment. Interesting, patients whose appetites were increased earlier in time were likely to gain more weight than patients whose appetites were increased later in time, and weight gain peaked at 1 month after increased appetite occurred. Although no significant difference was found in olanzapine-induced appetite between male and female, female patients were more likely to gain weight (P < 0.001). Therefore, appetite should be considered as an indicator for predicting olanzapine-induced weight gain, especially in female patients.

Olanzapine-treated patients exhibited an increase of more than 7% of initial body weight, which is consistent with previous findings (Gothelf et al., 2002; Wu et al., 2008). In addition to significant weight gain, patients with olanzapine treatment had significantly perturbed glucose and lipid metabolism after 12 weeks, which is consistent with previously published observations in patients with schizophrenia (Correll et al., 2011). Compared to patients in the unchanged appetite group, the increased appetite group had significant lipid abnormalities. Fasting glucose was not significantly different between the two groups. Participants with early increased appetite did not show increased velocity of insulin and insulin resistance index in the following months after increased appetite. It is possible that glucose levels are independent of weight gain, as appetite did not affect glucose levels.

Adverse physical health outcomes associated with antipsychotics, such as weight gain, metabolic disturbances, and related morbidity, have long been recognized (Wu et al., 2016). Previous studies have suggested that appetite may predict olanzapine-induced weight gain and adverse metabolic effects (Gothelf et al., 2002; Poyurovsky et al., 2007; Fountaine et al., 2010). To our knowledge, this is the first study to assess the association between appetite, weight gain, and metabolic disturbances after olanzapine treatment in drug-naive first-episode schizophrenia patients. Some findings give us more evidences about how to choose medication reasonably in clinic work and give more benefits for preventing olanzapine-induced weight gain and metabolic disturbances.
CONCLUSIONS

In conclusion, our study has shown that appetite is related to olanzapine-induced weight gain and dyslipidemia in drug-naïve first-episode patients with schizophrenia. Assessing appetite changes is an easy and practical way for weight gain prediction, which provides clinicians more time and options for intervention strategies. Early dietary inventions aimed at decreasing appetite and reducing food intake can be helpful for weight control in schizophrenia patients treated with olanzapine.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

This study was performed in accordance with the Declaration of Helsinki (G.A.o.t.W.M. Association, 2013), and approved by the Ethics Committee of the Second Xiangya Hospital, Central South University. After a complete description of the study to the participants, informed consent was obtained prior to study participation.

AUTHOR CONTRIBUTIONS

JH analyzed and interpreted the patient data and was a major contributor in writing the manuscript. G-RH mainly designed and performed the study. YeY, C-CL, J-MX, Y-JL, and X-JP helped in patient recruitment, monitor of the data quality, and document treatment emergent adverse events. YiY helped revised the manuscript. J-PZ guided the study design. RR-W was responsible for the overall content. All authors read and approved the final manuscript.

FUNDING

This work was supported by the Key R&D Program Projects, National Science Foundation of China (Grant No.2016YFC1306900) and the National Nature Science Foundation of China (Grant No.81622018 and No. 81901401).

ACKNOWLEDGMENTS

We would like to acknowledge the valued contribution of the participants and the support from their general practitioners. We also want to thank several anonymous reviewers for their valuable comments and suggestions to improve the quality of the paper.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00739/full#supplementary-material
SUPPLEMENT FIGURE 1 | Velocity of blood glucose and lipid changes in increased appetite group. The mean change values for each patient per month during the study period was analyzed at four time-points: before the month of time to increased appetite (-1M), the month of time to increased appetite (0M), 1 month after the month of time to increased appetite increase (+1M), and 2 months after the month of time to increased appetite (+2M).

SUPPLEMENT FIGURE 2 | Comparison of insulin and insulin resistance index change velocities of participants with increased appetite in different months. We compared the velocity of participants with an increased appetite within 4 weeks (A) and participants with an increased appetite between 4-8 weeks (B) in the month of time to increased appetite (0M) and 1 month after the month of time to increased appetite (+1M).

SUPPLEMENT TABLE 1 | Number of patients who had increased initial body weight by more than 7% or 10% at weeks 4, 8, and 12.

SUPPLEMENT TABLE 2 | Number of patients who had increased initial body weight by more than 7% or 10% at weeks 4, 8, and 12 in patients with increased appetite.

SUPPLEMENT TABLE 3 | Number of patients who had increased initial body weight by more than 7% or 10% at weeks 4, 8, and 12 in patients with unchanged appetite.

SUPPLEMENT TABLE 4 | Comparison of numbers of 7% or 10% weight gain between patients with increased appetite and patients with unchanged appetite at weeks 4, 8, and 12.

SUPPLEMENT TABLE 5 | The analysis of velocity of mean weight gain, glucose, and lipid changes in the appetite increased group at four time-points: before the month of time to appetite increase (-1M), the month of time to appetite increase (0M), 1 month after the month of time to appetite increase (+1M), and 2 months after the month of time to appetite increase (+2M). * indicates not significant, * indicates p-value < 0.05, ** indicates p-value < 0.01, *** indicates p-value < 0.001.

SUPPLEMENT TABLE 6 | Estimates of appetite effects on weight gain and metabolic-related outcome measures from general linear mixed model while controlling for age, duration of illness, and gender.

SUPPLEMENT TABLE 7-1 | The changes of weight, BMI, Insulin, IRI, and LDL-C per patient during the treatment period in different groups.

SUPPLEMENT TABLE 7-2 | Estimates of appetite effects on weight gain and metabolic-related outcome measures.

REFERENCES

Allison, D. B., Mentore, J. L., Heo, M., Chandler, I. P., Cappelleri, J. C., Infante, M. C., et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am. J. Psychiatry* 156, 1686–1696. doi: 10.1176/ajp.156.11.1686

Association, A.P. (2013). *Diagnosis and statistical manual of mental disorders (DSM-5)* (Arlington, VA: American Psychiatric Pub).

Basoglu, C., Oner, O., Gunes, C., Semiz, U. B., Ates, A. M., Algu, A., et al. (2010). ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. *Int. Clin. Psychopharmacol.* 25, 165–171. doi: 10.1097/YIC.0b0133283377850

Case, M., Treuer, T., Karagianis, J., and Hoffmann, V. P. (2010). The potential role of appetite in predicting weight changes during treatment with olanzapine. *BMC Psychiatry* 10, 72. doi: 10.1186/1471-244X-10-72

Cope, M., Nagy, T., Fernandez, J., Geary, N., Casey, D., and Allison, D. (2005). Antipsychotic drug-induced weight gain: development of an animal model. *Int. J. Obes.* 29, 607. doi: 10.1038/sj.ijo.0802928

Correll, C. U., Manu, P., Olshansky, V., Napolitano, B., Kane, J. M., and Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *Jama* 302, 1765–1773. doi: 10.1001/jama.2009.1549

Correll, C. U., Lenzc, T., and Malhotra, A. K. (2011). Antipsychotic drugs and obesity. *Trends Mol. Med.* 17, 97–107. doi: 10.1016/j.trendsmed.2010.10.010

Cui, H., Lopez, M., and Rahmouni, K. (2017). Ethnicity and excess mortality in severe mental illness: a cohort study. *Lancet Psychiatry* 2, 452–464. doi: 10.1016/S2215-0366(15)00115-7

Hillebrand, J. J., van Elburg, A. A., Kas, M. J., van Engeland, H., and Adan, R. A. (2005). Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? *Biol. Psychiatry* 58, 651–657.

Hu, D.-Y. (2017). New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China. *Chron. Dis. Trans. Med.* 3, 73. doi: 10.1016/j.cdtm.2016.11.001

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet* 394 (10202), 939–951. doi: 10.1016/S0140-6736(19)31135-3

Kafantaris, V., Leigh, E., Hertz, S., Berest, A., Schebendach, J., Sterling, W. M., et al. (2011). A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. *J. Child Adolesc. Psychopharmacol.* 21, 207–212. doi: 10.1089/cap.2010.0139

Kandors, B., Forse, R., and Blackburn, G. (1991). *Methods in obesity. Curr’s Current Therapy*. Ed. R. E. Rakel (Philadelphia: WB Saunders), 524–532.

Kluge, M., Schuld, A., Himmerich, H., Dalal, M., Schacht, A., Wehmeier, P. M., et al. (2007). Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. *J. Clin. Psychopharmacol.* 27, 662–666. doi: 10.1097/jcp.0b013e31815a8872

Koopmann, A., von der Goltz, C., Grosshans, M., Dinter, C., Vitale, M., Wiedemann, K., et al. (2012). The association of the appetitive peptide acylated ghrelin with alcohol craving in early abstinent alcohol dependent individuals. *Psychoneuroendocrinology* 37, 980–986. doi: 10.1016/j.psyneuen.2011.11.005

Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., and Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 373, 31–41. doi: 10.1016/S0140-6736 (08)61764-X

Leucht, S., Cipriani, A., Spino, L., Mavridis, D., Orey, D., Richter, F., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 382, 951–962. doi: 10.1016/S0140-6736(13)60733-3

}
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl. J. Med. 353, 1209–1223. doi: 10.1056/NEJMout051688

Lowette, K., Roosen, L., Tack, J., and Vanden Berghe, P. (2015). Effects of high-fructose diets on central appetite signaling and cognitive function. Front. Nutr. 2, 5. doi: 10.3389/fnut.2015.00005

Lu, M. L., Wang, T. N., Lin, T. Y., Shao, W. C., Chang, S. H., Chou, J. Y., et al. (2015). Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog. Neuropsychopharmacol. Biol. Psychiatry 58, 47–50.

Mancuso, C., Izquierdo, A., Slattery, M., Becker, K. R., Plessow, F., Thomas, J. J., et al. (2019). Changes in Appetite-Regulating Hormones Following Food Intake are Associated with Changes in Reported Appetite and a Measure of Hedonic Eating in Girls and Young Women with Anorexia Nervosa. Psychoneuroendocrinology 113, 104556. doi: 10.1016/j.psyneuen.2019.104556

McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., et al. (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164, 1050–1060. doi: 10.1176/ajp.2007.164.7.1050

Murashita, M., Kusumi, I., Inoue, T., Takahashi, Y., Hosoda, H., Kangawa, K., et al. (2005). Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30, 106–110. doi: 10.1016/j.psyneuen.2004.05.008

Newcomer, J. W. (2006). Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry 67, e16. doi: 10.4088/JCP.1106e16

Nielsen, M. Ø., Rostrup, E., Wulff, S., Glenthøj, B., and Ebdrup, B. H. (2016). Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment. JAMA Psychiatry 73, 121–128. doi: 10.1001/jamapsychiatry.2015.2582

Pawlowski, M., Abshir-Ahmed, Y., Bettiger, P., and Steiger, A. (2018). S241. Investigation of Mechanism of Increased Appetite After Olanzapine by sLORETA During Sleep. Biol. Psychiatry 83, S441–S442.

Perez-Cruzado, D., Cuesta-Vargas, A., Vera-Garcia, E., and Mayoral-Cleries, F. (2018). Medication and physical activity and physical fitness in severe mental illness. Psychiatry Res. 267, 19–24. doi: 10.1016/j.psychres.2018.05.055

Poyurovsky, M., Fuchs, C., Pashinin, A., Levi, A., Faragian, S., Maayan, R., et al. (2007). Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology 192, 441–448. doi: 10.1007/s00213-007-0731-1

Roerig, J. L., Mitchell, J. E., de Zwaan, M., Crosby, R. D., Gossnell, B. A., Steffen, K. J., et al. (2005). A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J. Clin. Psychopharmacol. 25, 413–418. doi: 10.1097/01.jcp.0000177549.36585.29

Sentissi, O., Epelbaum, J., Olie, J. P., and Poirier, M. (2008). Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr. Bull. 34, 1189–1199. doi: 10.1093/schbul/sbm141

Stip, E., Lungu, O. V., Anselmo, K., Letourneau, G., Mendrek, A., Stip, B., et al. (2012). Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl. Psychiatry 2, e128. doi: 10.1038/tp.2012.53

Sweeney, P., Li, C., and Yang, Y. (2017). Appetite suppressive role of medial septal glutamatergic neurons. Proc. Natl. Acad. Sci. 114, 13816–13821. doi: 10.1073/pnas.1707228114

Tan, L., Liu, J., Liu, X., Chen, J., Yan, Z., Yang, H., et al. (2009). Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J. Exp. Clin. Cancer Res. 28, 131. doi: 10.1186/1756-9966-28-131

Wu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., et al. (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. Jama 299, 185–193. doi: 10.1001/jama.2007.56-b

Wu, R., Zhang, F., Gao, K., Ou, J., Shao, P., Jin, H., et al. (2016). Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Mol. Psychiatry 21, 1537. doi: 10.1038/mp.2015.221

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Huang, Hei, Yang, Liu, Xiao, Long, Peng, Yang, Zhao and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.